Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8075229 | 1.00 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL4211457 | 1.00 | PTGS2 (0.71) | PTGS2PTGS1 | |
| SCHEMBL7112854 | 0.91 | PTGS2 (0.59) | PTGS2PTGS1 | |
| SCHEMBL8067207 | 0.91 | PTGS2 (0.69) | PTGS2PTGS1 | |
| SCHEMBL8080213 | 0.90 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL8076981 | 0.87 | PTGS2 (0.75) | PTGS2PTGS1 | |
| SCHEMBL8076878 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL8076957 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL8067255 | 0.87 | PTGS2 (0.70) | PTGS2PTGS1 | |
| SCHEMBL7624385 | 0.85 | PTGS2 (0.82) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6133292-A | NON-STEROIDAL ANTIINFLAMMATORY DRUG, INHIBIT HORMONE-INDUCED UTERINE CONTRACTIONS, ANTICARCINOGENIC AGENTS, ANTIPYRETICS; ANALGESICS; SIDE EFFECT REDUCTION; PREVENT THE SYNTHESIS OF CONTRACTILE PROSTANOIDS, DYSMENORRHEA, ASTHMA | MERCK FROSST CANADA & CO. (CA) | 2000-10-17 | — | — | US | claimed |
| EP-1028951-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2000-08-23 | — | — | EP | claimed |
| WO-1999023087-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-05-14 | — | — | WO | claimed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | ENGLEBIENNE & ASSOCIATES (BE) | 2009-08-06 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2009-07-30 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-7521435-B2 | Silicon containing compounds having selective COX-2 inhibitory activity and methods of making and using the same | PHARMA DIAGNOSTICS, N.V. (BE) | 2009-04-21 | — | — | US | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | CHEN YING-NAN PAN | 2008-09-18 | — | — | US | disclosed |
| EP-1443942-B1 | PHARMACEUTICAL COMPOSITION FOR USE FOR THE TREATMENT OF MALIGNANCIES COMPRISING IN COMBINATION A BISPHOSPHONATE, A COX-2 INHIBITOR AND A TAXOL | NOVARTIS AG (CH) | 2008-01-02 | — | — | EP | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | GARDELL STEPHEN J (US) | 2003-02-20 | — | — | US | disclosed |
| US-6133292-A | NON-STEROIDAL ANTIINFLAMMATORY DRUG, INHIBIT HORMONE-INDUCED UTERINE CONTRACTIONS, ANTICARCINOGENIC AGENTS, ANTIPYRETICS; ANALGESICS; SIDE EFFECT REDUCTION; PREVENT THE SYNTHESIS OF CONTRACTILE PROSTANOIDS, DYSMENORRHEA, ASTHMA | MERCK FROSST CANADA & CO. (CA) | 2000-10-17 | — | — | US | disclosed |
| US-6133292-A | NON-STEROIDAL ANTIINFLAMMATORY DRUG, INHIBIT HORMONE-INDUCED UTERINE CONTRACTIONS, ANTICARCINOGENIC AGENTS, ANTIPYRETICS; ANALGESICS; SIDE EFFECT REDUCTION; PREVENT THE SYNTHESIS OF CONTRACTILE PROSTANOIDS, DYSMENORRHEA, ASTHMA | MERCK FROSST CANADA & CO. (CA) | 2000-10-17 | — | — | US | disclosed |
| EP-1028951-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2000-08-23 | — | — | EP | disclosed |
| EP-1028951-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999023087-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-05-14 | — | — | WO | disclosed |
| WO-1999023087-A1 | DIARYL-5-ALKYL-5-METHYL-2(5H)-FURANONES AS SELECTIVE CYCLOOXYGENASE-2 INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192211-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885 |
| US-20080227845-A1 | CYCLOOXYGENASE-2 INHIBITOR/HISTONE DEACETYLASE INHIBITOR COMBINATION | HDAC2, HDAC9, HDAC1 | PTGS2 6/4885PTGS1 13/4885 |
| US-20030035795-A1 | Methods for treating or reducing the risk of pain and inflammatory disorders by administering inhibitors of activated thrombin activatable fibrinolysis inhibitor | BPGM, PLG, FGB | PTGS2 372/4885PTGS1 206/4885 |
| US-20090197833-A1 | Silicon Containing Compounds Having Selective Cox-2 Inhibitory Activity and Methods of Making and Using the Same | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.